Click here to download brochure
|Module 1: Breast Carcinogenesis & Management of High-Risk Disease|
|Module 2: Breast Imaging|
|Module 3: Breast Surgery|
|Module 4: Breast Radiation Therapy|
|Module 5: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy|
|Module 6: Treatment of HER2-Positive Disease|
|Module 7: Systemic Treatment of Advanced/Metastatic Disease|
|Module 8: Organ-Targeted Treatment of Metastatic Disease|
|Module 9: Toxicity Management and Survivorship Considerations|
Click here to see the full agenda and session titles.
The following individuals have no relevant financial relationships with commercial interests to disclose:
David Euhus, MD, FACS; Carol Fabian, MD; William J. Gradishar, MD, FASCO, FACP; Karin Hahn, MD, MSc, MPH; Syed A. Hoda, MD; Frankie Ann Holmes, MD, FACP; Anne McTiernan, MD, PhD; Anne Moore, MD; Soonmyung Paik, MD; David M. Schuster, MD; Lawrence J. Solin, MD, FACR, FASTRO; Jeffrey N. Weitzel, MD; Suzanna Zick, ND, MPH
The staff of Physicians’ Education Resource®, LLC.
The following individuals have relevant financial relationships with commercial interests to disclose:
Carey K. Anders, MD – Consultant: Novartis, Sanofi, to-BBB Therapeutics, Geron, AngioChem, Merrimack Pharmaceuticals, Lilly, Genentech, Nektar Therapeutics, Kadmon Corporation; Research Funding: Novartis, Sanofi, to-BBB Therapeutics, Geron, AngioChem, Merrimack Pharmaceuticals, Puma Biotechnology, Lilly, Kadmon Corporation – all uncompensated; Douglas W. Arthur, MD – Consultant: ImpediMed, Advanced Radiation Therapy; Claudine Isaacs, MD – Grant/ Research Support: Novartis; Speaker’s Bureau: Genentech, Celgene Corporation; Henry M. Kuerer, MD, PhD, FACS – Grant/ Research Support: Genomic Health; Consultant: Gerson Lehrman Group, Lightpoint Medical, Inc.; Other: McGraw-Hill Publishing; Charles Loprinzi, MD – Grant/Research Support: Bristol-Myers Squibb, Pfizer, Janssen; Consultant: Cubist Pharmaceuticals, Mitsubishi Tanabe Pharma, PledPharma; Eleftherios Mamounas, MD, MPH, FACS – Consultant: Genomic Health, Celgene Corporation, Pfizer, Novartis; Speaker’s Bureau: Genomic Health, Roche/ Genentech; Ruth O’Regan, MD – Consultant: Genentech, Pfizer, AstraZeneca; Joyce O’Shaughnessy, MD – Advisory Board/ Consultant: Arno Therapeutics, Celgene Corporation, Corcept Therapeutics, Eisai, Genentech, GlaxoSmithKline, Johnson & Johnson, Lilly, med fusion, Merrimack Pharmaceuticals, Millennium: The Takeda Oncology Company, Novartis, Pfizer, sanofi-aventis; Lori J. Pierce, MD, FASTRO – Shareholder: PFS Genomics (founder's shares); Elizabeth Rafferty, MD – Grant/Research Support: Principal Investigator, Research Grant from Hologic, Inc. for investigation of breast tomosynthesis; Edward H. Romond, MD – Grant/ Research Support: Genentech/ Roche; Hope S. Rugo, MD – Speakers Bureau: Genomic Health; Grant/Research Support: Amgen Inc., Eisai, Genentech, GlaxoSmithKline, Lilly, MacroGenics, Inc., Merck & Co., Inc., Novartis, OBI Pharma, Inc., Pfizer, Plexxikon Inc., Roche; Hani Sbitany, MD – Speaker’s Bureau: LifeCell; Joseph Sparano, MD – AstraZeneca, Novartis, Celgene Corporation, Genentech/Roche, Lilly, Celldex Therapeutics; Catherine Van Poznak, MD – Grant/Research Support: Bayer
It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Jan 30, 2018
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid Malignancies
Jan 30, 2018
Cancer Summaries and Commentaries™: Update from San Diego - Advances in the Treatment of Multiple Myeloma
Jan 31, 2018
Jan 31, 2018